|
|||||
|
|
Lower risk of hospitalization for heart failure,kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care |
|
| Authors: | Iskandar Idris DM Ruiqi Zhang MSc Jil Billy Mamza PhD Mike Ford BSc Tamsin Morris BSc Amitava Banerjee DPhil Kamlesh Khunti MD |
| Affiliation: | 1. Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK;2. Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK;3. Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK;4. Institute of Health Informatics, University College, London, UK Department of Cardiology, University College London Hospitals, London, UK;5. Diabetes Research Centre, University of Leicester, Leicester, UK |
| Abstract: | |
| Keywords: | cardiovascular disease clinical trial dapagliflozin diabetes complications dipeptidyl peptidase-4 inhibitor heart failure |